A study to investigate the drug-drug interactions between ACT-541468 and ethanol in healthy subjects
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Enrollment
22
One tablet of 50 mg ACT-541468 will be administered orally.
Matching ACT-541468 placebo will be administered orally as 1 tablet.
Ethanol 10% w/v solution in 5% glucose will be administered i.v. for 5 h and clamped at an ethanol level of 0.6 g/L.
Centre For Human Drug Research
Leiden, Netherlands
Change from baseline for saccadic peak velocity (degrees/sec) to assess sedation
Time frame: Several timepoints on Day 1; for up to 24 hours post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Matching placebo for the ethanol infusion (i.e., 5% glucose solution) will be administered i.v. for 5 h.